Glenmark Pharmaceuticals Intrinsic Value
Glenmark Pharmaceuticals (GLENMARK) median intrinsic value is ₹2480.38 from 9 valuation models (range ₹715–₹5962), vs current price ₹2384.90 — +4.0% upside (Trading Near Calculated Value), margin of safety 3.8%. Also explore Glenmark Pharmaceuticals share price performance to track price trends across different timeframes.
GLENMARK Valuation Methods Summary — DCF, Graham Number & P/E
Glenmark Pharmaceuticals intrinsic value across 9 models vs current price ₹2384.90 — upside/downside and value range per method. Browse GLENMARK cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1903.44 | ₹1522.75 - ₹2284.13 | -20.2% | EPS: ₹86.52, Sector P/E: 22x |
| Book Value Method | asset | ₹5962.25 | ₹5366.03 - ₹6558.48 | +150.0% | Book Value/Share: ₹3160.36, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4769.80 | ₹4292.82 - ₹5246.78 | +100.0% | Revenue/Share: ₹8862.86, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4769.80 | ₹4292.82 - ₹5246.78 | +100.0% | EBITDA: ₹4528.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2072.28 | ₹1657.82 - ₹2486.74 | -13.1% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹715.47 | ₹643.92 - ₹787.02 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1336.73 | ₹1203.06 - ₹1470.40 | -44.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4769.80 | ₹4292.82 - ₹5246.78 | +100.0% | ROE: 27.6%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹2480.38 | ₹2232.34 - ₹2728.42 | +4.0% | EPS: ₹86.52, BVPS: ₹3160.36 |
GLENMARK Intrinsic Value vs Market Price — All Valuation Models
Glenmark Pharmaceuticals fair value range ₹715–₹5962 vs current market price ₹2384.90 across 9 valuation models. For current market price and key ratios, visit Glenmark Pharmaceuticals share price chart.
GLENMARK Intrinsic Value Analysis — Undervalued or Overvalued?
Glenmark Pharmaceuticals median intrinsic value ₹2480.38, current price ₹2384.90 — Trading Near Calculated Value by 4.0%, margin of safety 3.8%.
What is the intrinsic value of GLENMARK?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Glenmark Pharmaceuticals (GLENMARK) is ₹2480.38 (median value). With the current market price of ₹2384.90, this represents a +4.0% variance from our estimated fair value.
The valuation range spans from ₹715.47 to ₹5962.25, indicating ₹715.47 - ₹5962.25.
Is GLENMARK undervalued or overvalued?
Based on our multi-method analysis, Glenmark Pharmaceuticals (GLENMARK) appears to be trading near calculated value by approximately 4.0%.
GLENMARK Financial Health — Key Ratios vs Industry Benchmarks
Glenmark Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.53 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 27.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 16.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.55x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
GLENMARK Cash Flow Quality — Operating & Free Cash Flow
Glenmark Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-828 Cr | ₹-828 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-265 Cr | ₹-265 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹625 Cr | ₹368 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1,109 Cr | ₹951 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,131 Cr | ₹800 Cr | Positive Free Cash Flow | 8/10 |